In 2021, Li et al. reported that carvacrol dose-dependently inhibited viability in multiple BC cell lines (BT-483, BT-474, MCF-7, MDA-MB-231, MDA-MB-453) and suppressed TRPM7 channel activity (IC50 ≈ 83.8 μM), with marked inhibition at 200 μM. Here, TRPM7 is linked to breast cancer.